Related Experiment Video
Updated: May 16, 2025
06:50
Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions
Published on: January 26, 2024
962
Introducing the Potential Binding Interface between the TRAIL-Mimicking Peptide and DR5 via Alanine Scan
Nitesh Mani Tripathi1, Arnab Chowdhury1, Neelam Verma1
1Biomimetic Peptide Engineering Laboratory, Indian Institute of Technology, Ropar, Punjab 140001, India.
ACS Medicinal Chemistry Letters
|May 14, 2025
Summary
Researchers mapped key interactions between a peptide agonist and death receptor 5 (DR5). This peptide mimics TRAIL and shows potential for developing new cancer therapies by inducing apoptosis.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Death receptor 5 (DR5) is a target for cancer therapy.
- TRAIL is the natural ligand for DR5, but its therapeutic use is limited.
- Peptide agonists offer an alternative for DR5-mediated apoptosis induction.
Purpose of the Study:
- To investigate the binding interface between a peptide agonist (P) and DR5.
- To identify critical residues of peptide P involved in DR5 binding.
- To guide the development of novel peptide-based DR5 agonists.
Main Methods:
- Alanine scanning mutagenesis of peptide P.
- Antiproliferative activity assays using HCT116 cancer cells.
- In silico molecular docking and molecular dynamics (MD) simulations.
Main Results:
- Identified "hot-spot" residues (Trp1, Leu4, Arg7, Ile8, Gln12, Arg15) on peptide P crucial for DR5 interaction.
- Experimental data on residue importance was supported by in silico modeling.
- Mapped the 3D binding interface between peptide P and DR5.
Conclusions:
- The study elucidates the molecular basis of peptide P binding to DR5.
- Key residues are identified for optimizing peptide agonist design.
- This research facilitates the development of next-generation peptide agonists for cancer treatment via apoptosis induction.
